Hydrogen sulfide preserves endothelial nitric oxide synthase function by inhibiting proline-rich kinase 2: Implications for cardiomyocyte survival and cardioprotection

Molecular Pharmacology

Volumn 92, Issue 6, 2017, Pages 718-730

  Bibli, Sofia Iris ^a,b   Szabo, Csaba ^c   Chatzianastasiou, Athanasia ^a   Luck, Bert ^b   Zukunft, Sven ^b   Fleming, Ingrid ^b   Papapetropoulos, Andreas ^a,d  

^a UNIVERSITY OF ATHENS   (Greece)

^b GOETHE UNIVERSITY   (Germany)

^c University of Texas Medical Branch School of Medicine   (United States)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOCAL ADHESION KINASE 2; HYDROGEN SULFIDE; REACTIVE OXYGEN METABOLITE; SODIUM SULFIDE; CARDIOTONIC AGENT; CYSTATHIONINE GAMMA LYASE; HYDROGEN PEROXIDE; NITRIC OXIDE; PROLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; H9C2(2-1) CELL LINE; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SUPPLEMENTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM;

ANIMALS; CARDIOTONIC AGENTS; CELL LINE; CYSTATHIONINE GAMMA-LYASE; CYSTEINE; FOCAL ADHESION KINASE 2; HEK293 CELLS; HUMANS; HYDROGEN PEROXIDE; HYDROGEN SULFIDE; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROLINE; RATS;

EID: 85034620102     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.117.109645     Document Type: Article

References (71)

1. Altaany Z, Ju Y, Yang G, and Wang R (2014) The coordination of S-sulfhydration, S-nitrosylation, and phosphorylation of endothelial nitric oxide synthase by hydrogen sulfide. Sci Signal 7:ra87.
2. Altaany Z, Yang G, and Wang R (2013) Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells. J Cell Mol Med 17:879-888.
3. Andreadou I, Iliodromitis EK, Rassaf T, Schulz R, Papapetropoulos A, and Ferdinandy P (2015) The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br J Pharmacol 172:1587-1606.
4. Andreadou I, Mikros E, IoannidisK, SigalaF, NakaK, KostidisS, Farmakis D, TentaR, Kavantzas N, Bibli SI, et al. (2014) Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. J Mol Cell Cardiol 69:4-16.
5. Asimakopoulou A, Panopoulos P, Chasapis CT, Coletta C, Zhou Z, Cirino G, Giannis A, Szabo C, Spyroulias GA, and Papapetropoulos A (2013) Selectivity of commonly used pharmacological inhibitors for cystathionine b synthase (CBS) and cystathionine g lyase (CSE). Br J Pharmacol 169:922-932.
6. Bibli SI, Andreadou I, Chatzianastasiou A, Tzimas C, Sanoudou D, Kranias E, Brouckaert P, Coletta C, Szabo C, Kremastinos DT, et al. (2015a) Cardioprotection by H2S engages a cGMP-dependent protein kinase G/phospholamban pathway. Cardiovasc Res 106:432-442.
7. Bibli SI, Yang G, Zhou Z, Wang R, Topouzis S, and Papapetropoulos A (2015b) Role of cGMP in hydrogen sulfide signaling. Nitric Oxide 46:7-13.
8. Bibli SI, Zhou Z, Zukunft S, Fisslthaler B, Andreadou I, Szabo C, Brouckaert P, Fleming I, and Papapetropoulos A (2017) Tyrosine phosphorylation of ENOS regulates myocardial survival after an ischaemic insult: Role of PYK2. Cardiovasc Res 113:926-937.
9. Bir SC, Kolluru GK, McCarthy P, Shen X, Pardue S, Pattillo CB, and Kevil CG (2012) Hydrogen sulfide stimulates ischemic vascular remodeling through nitric oxide synthase and nitrite reduction activity regulating hypoxia-inducible factor-1a and vascular endothelial growth factor-dependent angiogenesis. J Am Heart Assoc 1: E004093.
10. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, Roviezzo F, Brancaleone V, and Cirino G (2010) Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol 30:1998-2004.
11. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Zaid A, Giannogonas P, Cantalupo A, Dhayade S, Karalis KP, Wang R, et al. (2012) cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation. PLoS One 7:e53319.
12. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, and Lefer DJ (2009) Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 105:365-374.
13. Chappell AE, Bunz M, Smoll E, Dong H, Lytle C, Barrett KE, and McCole DF (2008) Hydrogen peroxide inhibits Ca21-dependent chloride secretion across colonic epithelial cells via distinct kinase signaling pathways and ion transport proteins. FASEB J 22:2023-2036.
14. Chatzianastasiou A, Bibli SI, Andreadou I, Efentakis P, Kaludercic N, Wood ME, Whiteman M, Di Lisa F, Daiber A, Manolopoulos VG, et al. (2016) Cardioprotection by H2S donors: nitric oxide-dependent and -independent mechanisms. J Pharmacol Exp Ther 358:431-440.
15. Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Módis K, Panopoulos P, Asimakopoulou A, Gerö D, Sharina I, Martin E, et al. (2012) Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci USA 109: 9161-9166.
16. Das A, Samidurai A, Hoke NN, Kukreja RC, and Salloum FN (2015) Hydrogen sulfide mediates the cardioprotective effects of gene therapy with PKG-Ia. Basic Res Cardiol 110:42.
17. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, and Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605.
18. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, et al. (2007) Hydrogen sulfide attenuates myocardial ischemiareperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci USA 104:15560-15565.
19. Fisslthaler B, Loot AE, Mohamed A, Busse R, and Fleming I (2008) Inhibition of endothelial nitric oxide synthase activity by proline-rich tyrosine kinase 2 in response to fluid shear stress and insulin. Circ Res 102:1520-1528.
20. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, and Sessa WC (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399:597-601.
21. Greaney JL, Kutz JL, Shank SW, Jandu S, Santhanam L, and Alexander LM (2017) Impaired hydrogen sulfide-mediated vasodilation contributes to microvascular endothelial dysfunction in hypertensive adults. Hypertension 69:902-909.
22. Hausenloy DJ and Yellon DM (2016) Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol 13:193-209.
23. Hirotani S, Higuchi Y, Nishida K, Nakayama H, Yamaguchi O, Hikoso S, Takeda T, Kashiwase K, Watanabe T, Asahi M, et al. (2004) Ca(21)-sensitive tyrosine kinase Pyk2/CAK beta-dependent signaling is essential for G-protein-coupled receptor agonist-induced hypertrophy. J Mol Cell Cardiol 36:799-807.
24. Johansen D, Ytrehus K, and Baxter GF (2006) Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury-Evidence for a role of K ATP channels. Basic Res Cardiol 101:53-60.
25. Jones SP and Bolli R (2006) The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40:16-23.
26. Ju Y, Zhang W, Pei Y, and Yang G (2013) H(2)S signaling in redox regulation of cellular functions. Can J Physiol Pharmacol 91:8-14.
27. Kabil O and Banerjee R (2014) Enzymology of H2S biogenesis, decay and signaling. Antioxid Redox Signal 20:770-782.
28. Kabil O, Motl N, and Banerjee R (2014) H2S and its role in redox signaling. Biochim Biophys Acta 1844:1355-1366.
29. Kanagy NL, Szabo C, and Papapetropoulos A (2017) Vascular biology of hydrogen sulfide. Am J Physiol Cell Physiol 312:C537-C549.
30. Karwi QG, Bornbaum J, Boengler K, Torregrossa R, Whiteman M, Wood ME, Schulz R, and Baxter GF (2017) AP39, a mitochondria-targeting hydrogen sulfide (H2 S) donor, protects against myocardial reperfusion injury independently of salvage kinase signalling. Br J Pharmacol 174:287-301.
31. Katsouda A, Bibli SI, Pyriochou A, Szabo C, and Papapetropoulos A (2016) Regulation and role of endogenously produced hydrogen sulfide in angiogenesis. Pharmacol Res 113 (Pt A):175-185.
32. Kimura H (2011) Hydrogen sulfide: Its production, release and functions. Amino Acids 41:113-121.
33. King AL, Polhemus DJ, Bhushan S, Otsuka H, Kondo K, Nicholson CK, Bradley JM, Islam KN, Calvert JW, Tao YX, et al. (2014) Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. Proc Natl Acad Sci USA 111:3182-3187.
34. Kondo K, Bhushan S, King AL, Prabhu SD, Hamid T, Koenig S, Murohara T, Predmore BL, Gojon G, Sr, Gojon G, Jr, et al. (2013) H2S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation 127:1116-1127.
35. Koshman YE, Chu M, Kim T, Kalmanson O, Farjah M, Kumar M, Lewis W, Geenen DL, de Tombe P, Goldspink PH, et al. (2014) Cardiomyocyte-specific expression of CRNK, the C-terminal domain of PYK2, maintains ventricular function and slows ventricular remodeling in a mouse model of dilated cardiomyopathy. J Mol Cell Cardiol 72:281-291.
36. Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B, and Schlessinger J (1995) Protein tyrosine kinase PYK2 involved in Ca(21)-induced regulation of ion channel and MAP kinase functions. Nature 376:737-745.
37. Li L, Rose P, and Moore PK (2011) Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol 51:169-187.
38. Li Q and Lancaster JR, Jr (2013) Chemical foundations of hydrogen sulfide biology. Nitric Oxide 35:21-34.
39. Loot AE, Schreiber JG, Fisslthaler B, and Fleming I (2009) Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med 206:2889-2896.
40. Meng J, Ganesan Adaikan P, and Srilatha B (2013) Hydrogen sulfide promotes nitric oxide production in corpus cavernosum by enhancing expression of endothelial nitric oxide synthase. Int J Impot Res 25:86-90.
41. Minamishima S, Bougaki M, Sips PY, Yu JD, Minamishima YA, Elrod JW, Lefer DJ, Bloch KD, and Ichinose F (2009) Hydrogen sulfide improves survival after cardiac arrest and cardiopulmonary resuscitation via a nitric oxide synthase 3-dependent mechanism in mice. Circulation 120:888-896.
42. Módis K, Bos EM, Calzia E, van Goor H, Coletta C, Papapetropoulos A, Hellmich MR, Radermacher P, Bouillaud F, and Szabo C (2014) Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. Pathophysiological and therapeutic aspects. Br J Pharmacol 171:2123-2146.
43. Mustafa AK, Gadalla MM, Sen N, Kim S, Mu W, Gazi SK, Barrow RK, Yang G, Wang R, and Snyder SH (2009) H2S signals through protein S-sulfhydration. Sci Signal 2:ra72.
44. Olson SD (2013) Fluid dynamic model of invertebrate sperm chemotactic motility with varying calcium inputs. J Biomech 46:329-337.
45. Pan TT, Feng ZN, Lee SW, Moore PK, and Bian JS (2006) Endogenous hydrogen sulfide contributes to the cardioprotection by metabolic inhibition preconditioning in the rat ventricular myocytes. J Mol Cell Cardiol 40:119-130.
46. Papapetropoulos A, Foresti R, and Ferdinandy P (2015) Pharmacology of the 'gasotransmitters' NO, CO and H2S: Translational opportunities. Br J Pharmacol 172:1395-1396.
47. Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, Jeschke MG, Branski LK, Herndon DN, Wang R, et al. (2009) Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci USA 106: 21972-21977.
48. Paul BD and Snyder SH (2012) H2S signalling through protein sulfhydration and beyond. Nat Rev Mol Cell Biol 13:499-507.
49. Peake BF, Nicholson CK, Lambert JP, Hood RL, Amin H, Amin S, and Calvert JW (2013) Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erk-dependent manner. Am J Physiol Heart Circ Physiol 304:H1215-H1224.
50. Polhemus D, Kondo K, Bhushan S, Bir SC, Kevil CG, Murohara T, Lefer DJ, and Calvert JW (2013) Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. Circ Heart Fail 6:1077-1086.
51. Polhemus DJ, Calvert JW, Butler J, and Lefer DJ (2014) The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure. Scientifica (Cairo) 2014:768607.
52. Polhemus DJ and Lefer DJ (2014) Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. Circ Res 114:730-737.
53. Predmore BL, Kondo K, Bhushan S, Zlatopolsky MA, King AL, Aragon JP, Grinsfelder DB, Condit ME, and Lefer DJ (2012) The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability. Am J Physiol Heart Circ Physiol 302:H2410-H2418.
54. Salloum FN (2015) Hydrogen sulfide and cardioprotection-Mechanistic insights and clinical translatability. Pharmacol Ther 152:11-17.
55. Shibuya N, Koike S, Tanaka M, Ishigami-Yuasa M, Kimura Y, Ogasawara Y, Fukui K, Nagahara N, and Kimura H (2013) A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells. Nat Commun 4:1366.
56. Shimizu Y, Nicholson CK, Lambert JP, Barr LA, Kuek N, Herszenhaut D, Tan L, Murohara T, Hansen JM, Husain A, et al. (2016) Sodium sulfide attenuates ischemic-induced heart failure by enhancing proteasomal function in an Nrf2-dependent manner. Circ Heart Fail 9:e002368.
57. SunWH, Liu F, Chen Y, and Zhu YC (2012)Hydrogen sulfide decreases the levels ofROS by inhibiting mitochondrial complex IV and increasing SOD activities in cardiomyocytes under ischemia/reperfusion. Biochem Biophys Res Commun 421:164-169.
58. Szabó C (2007) Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6:917-935.
59. Szabo C (2017) Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: Mechanisms and implications. Am J Physiol Cell Physiol 312:C3-C15.
60. Szabó C and Papapetropoulos A (2011) Hydrogen sulphide and angiogenesis: Mechanisms and applications. Br J Pharmacol 164:853-865.
61. Szabó G, Veres G, Radovits T, Gero D, Módis K, Miesel-Gröschel C, Horkay F, Karck M, and Szabó C (2011) Cardioprotective effects of hydrogen sulfide. Nitric Oxide 25: 201-210.
62. Tai LK, Okuda M, Abe J, Yan C, and Berk BC (2002) Fluid shear stress activates proline-rich tyrosine kinase via reactive oxygen species-dependent pathway. Arterioscler Thromb Vasc Biol 22:1790-1796.
63. Takeishi Y (2014) Pivotal roles of regulating the proline-rich tyrosine kinase 2 (PYK2) signaling in cardiac function and remodeling. J Mol Cell Cardiol 74:295-296.
64. Tokiwa G, Dikic I, Lev S, and Schlessinger J (1996) Activation of Pyk2 by stress signals and coupling with JNK signaling pathway. Science 273:792-794.
65. Wang R (2012) Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. Physiol Rev 92:791-896.
66. Wang R, Szabo C, Ichinose F, Ahmed A, Whiteman M, and Papapetropoulos A (2015) The role of H2S bioavailability in endothelial dysfunction. Trends Pharmacol Sci 36:568-578.
67. Xie ZZ, Liu Y, and Bian JS (2016) Hydrogen sulfide and cellular redox homeostasis. Oxid Med Cell Longev 2016:6043038.
68. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, et al. (2008) H2S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine gamma-lyase. Science 322:587-590.
69. Yellon DM and Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121-1135.
70. Zhao Y, Yang C, Organ C, Li Z, Bhushan S, Otsuka H, Pacheco A, Kang J, Aguilar HC, Lefer DJ, et al. (2015) Design, synthesis, and cardioprotective effects of N-mercapto-based hydrogen sulfide donors. J Med Chem 58:7501-7511.
71. Zhou Z, Martin E, Sharina I, Esposito I, Szabo C, Bucci M, Cirino G, and Papapetropoulos A (2016) Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide. Pharmacol Res 111:556-562.